The results showed that the mRNA levels of IL-1β, IL-6, IL-8, and IL-18 were significantly reduced in the drug treatment groups compared to the LPS group, which is consistent with results from other studies using TCMF treatments for endometritis. The gene discussed is IL6; the disease is endometritis.